A Vagionas, I Balgkouranidou, T Koukaki, E Biziota, K Amarantidis, S Kakolyris, N Xenidis
{"title":"循环细胞游离 DNA 转移性结直肠癌患者 SOX17 和 WNT5a 启动子甲基化状态的预后意义","authors":"A Vagionas, I Balgkouranidou, T Koukaki, E Biziota, K Amarantidis, S Kakolyris, N Xenidis","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Carcinogenesis of colorectal cancer is a process involving genetic mutations and epigenetic alterations in its multiple phases. The most considerable epigenetic alteration occurring in colorectal cancer (CRC) tumorigenesis is the methylation-mediated silencing of tumor suppressor genes. The present study aimed to detect the methylation status of <i>SOX17</i> and <i>WNT5a</i> promoters in cell-free DNA circulating in plasma of metastatic CRC patients and to investigate potential prognostic correlation.</p><p><strong>Methods: </strong>A methylation-specific real-time polymerase chain reaction was utilized to investigate the methylation status of genes (<i>SOX17</i> and <i>WNT5a</i>) promoter in the blood of 85 metastatic CRC patients.</p><p><strong>Results: </strong>We found the <i>SOX17</i> promoter methylated in 54/85 (63.5 %) while <i>WNT5a</i> was methylated in 39/85 (45.8 %) samples of the advanced CRC. All control samples were negative for <i>SOX17</i> and <i>WNT5a</i> promoter methylation. Patients with metastatic CRC and methylated <i>SOX17 and WNT5a</i> promoter status had a significantly poorer outcome than patients with non-methylated ones.</p><p><strong>Conclusions: </strong>Plasma <i>SOX17</i> and <i>WNT5a</i> promoter methylation are frequent epigenetic events in advanced CRC. The reported correlations between the methylation status of genes (SOX17 and Wnt5a) promoter and poorer survival in patients with advanced CRC disease agree with the proposed role of <i>SOX17</i> as a tumor suppressor gene. A more considerable CRC patient cohort is required to research these findings' potential further and investigate whether <i>SOX17</i> in plasma could serve as a useful prognostic biomarker in metastatic CRC. HIPPOKRATIA 2023, 27 (1):7-11.</p>","PeriodicalId":50405,"journal":{"name":"Hippokratia","volume":"27 1","pages":"7-11"},"PeriodicalIF":0.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908310/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic significance of <i>SOX17</i> and <i>WNT5a</i> promoter methylation status in circulating cell-free DNA metastatic colorectal cancer patients.\",\"authors\":\"A Vagionas, I Balgkouranidou, T Koukaki, E Biziota, K Amarantidis, S Kakolyris, N Xenidis\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Carcinogenesis of colorectal cancer is a process involving genetic mutations and epigenetic alterations in its multiple phases. The most considerable epigenetic alteration occurring in colorectal cancer (CRC) tumorigenesis is the methylation-mediated silencing of tumor suppressor genes. The present study aimed to detect the methylation status of <i>SOX17</i> and <i>WNT5a</i> promoters in cell-free DNA circulating in plasma of metastatic CRC patients and to investigate potential prognostic correlation.</p><p><strong>Methods: </strong>A methylation-specific real-time polymerase chain reaction was utilized to investigate the methylation status of genes (<i>SOX17</i> and <i>WNT5a</i>) promoter in the blood of 85 metastatic CRC patients.</p><p><strong>Results: </strong>We found the <i>SOX17</i> promoter methylated in 54/85 (63.5 %) while <i>WNT5a</i> was methylated in 39/85 (45.8 %) samples of the advanced CRC. All control samples were negative for <i>SOX17</i> and <i>WNT5a</i> promoter methylation. Patients with metastatic CRC and methylated <i>SOX17 and WNT5a</i> promoter status had a significantly poorer outcome than patients with non-methylated ones.</p><p><strong>Conclusions: </strong>Plasma <i>SOX17</i> and <i>WNT5a</i> promoter methylation are frequent epigenetic events in advanced CRC. The reported correlations between the methylation status of genes (SOX17 and Wnt5a) promoter and poorer survival in patients with advanced CRC disease agree with the proposed role of <i>SOX17</i> as a tumor suppressor gene. A more considerable CRC patient cohort is required to research these findings' potential further and investigate whether <i>SOX17</i> in plasma could serve as a useful prognostic biomarker in metastatic CRC. HIPPOKRATIA 2023, 27 (1):7-11.</p>\",\"PeriodicalId\":50405,\"journal\":{\"name\":\"Hippokratia\",\"volume\":\"27 1\",\"pages\":\"7-11\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10908310/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hippokratia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hippokratia","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Prognostic significance of SOX17 and WNT5a promoter methylation status in circulating cell-free DNA metastatic colorectal cancer patients.
Aim: Carcinogenesis of colorectal cancer is a process involving genetic mutations and epigenetic alterations in its multiple phases. The most considerable epigenetic alteration occurring in colorectal cancer (CRC) tumorigenesis is the methylation-mediated silencing of tumor suppressor genes. The present study aimed to detect the methylation status of SOX17 and WNT5a promoters in cell-free DNA circulating in plasma of metastatic CRC patients and to investigate potential prognostic correlation.
Methods: A methylation-specific real-time polymerase chain reaction was utilized to investigate the methylation status of genes (SOX17 and WNT5a) promoter in the blood of 85 metastatic CRC patients.
Results: We found the SOX17 promoter methylated in 54/85 (63.5 %) while WNT5a was methylated in 39/85 (45.8 %) samples of the advanced CRC. All control samples were negative for SOX17 and WNT5a promoter methylation. Patients with metastatic CRC and methylated SOX17 and WNT5a promoter status had a significantly poorer outcome than patients with non-methylated ones.
Conclusions: Plasma SOX17 and WNT5a promoter methylation are frequent epigenetic events in advanced CRC. The reported correlations between the methylation status of genes (SOX17 and Wnt5a) promoter and poorer survival in patients with advanced CRC disease agree with the proposed role of SOX17 as a tumor suppressor gene. A more considerable CRC patient cohort is required to research these findings' potential further and investigate whether SOX17 in plasma could serve as a useful prognostic biomarker in metastatic CRC. HIPPOKRATIA 2023, 27 (1):7-11.
期刊介绍：
Hippokratia journal is a quarterly issued, open access, peer reviewed, general medical journal, published in Thessaloniki, Greece. It is a forum for all medical specialties. The journal is published continuously since 1997, its official language is English and all submitted manuscripts undergo peer review by two independent reviewers, assigned by the Editor (double blinded review process).
Hippokratia journal is managed by its Editorial Board and has an International Advisory Committee and over 500 expert Reviewers covering all medical specialties and additionally Technical Reviewers, Statisticians, Image processing Experts and a journal Secretary. The Society “Friends of Hippokratia Journal” has the financial management of both the printed and electronic edition of the journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
